Immunotherapy for ankylosing spondylitis

Kyle Vogan
DOI: https://doi.org/10.1038/s41588-023-01612-7
IF: 30.8
2023-12-09
Nature Genetics
Abstract:Genetic susceptibility to ankylosing spondylitis, a debilitating autoimmune disease characterized by inflammation of the joints and ligaments of the spine, is strongly associated with the HLA-B*27:05 allele. Recent studies have further identified a specific TRBV9-containing CD8 + T cell receptor (TCR) motif enriched in the peripheral blood and synovial fluid of individuals with ankylosing spondylitis and related autoimmune diseases, which suggests that interactions between HLA-B*27 and TRBV9 + CD8 + T cell clones might be a key driver of disease pathology. To explore the therapeutic potential of targeting this interaction, Britanova et al. used a cytotoxic anti-TRBV9 antibody to deplete T cells carrying TRBV9 + TCRs in a patient with ankylosing spondylitis. They found that this treatment effectively depleted TRBV9 + T cells and resulted in a strong clinical response within 3 months, with complete remission persisting for 4 years so far with a regimen of anti-TRBV9 injections administered every 4 months. The promising results of this single case study suggest that anti-TRBV9 therapy could be an effective treatment for ankylosing spondylitis and other HLA-B*27-associated autoimmune diseases.
genetics & heredity
What problem does this paper attempt to address?